Amgen Inc. (NASDAQ:AMGN) Position Increased by Check Capital Management Inc. CA

Check Capital Management Inc. CA grew its position in Amgen Inc. (NASDAQ:AMGN) by 2.0% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,795 shares of the medical research company’s stock after buying an additional 75 shares during the quarter. Amgen makes up approximately 0.0% of Check Capital Management Inc. CA’s portfolio, making the stock its 21st largest position. Check Capital Management Inc. CA’s holdings in Amgen were worth $1,223,000 at the end of the most recent reporting period.

Several other institutional investors have also made changes to their positions in AMGN. Capital Performance Advisors LLP purchased a new position in Amgen during the 3rd quarter worth approximately $25,000. Strategic Financial Concepts LLC acquired a new stake in shares of Amgen in the second quarter worth $26,000. Hershey Financial Advisers LLC acquired a new position in Amgen during the second quarter valued at $30,000. nVerses Capital LLC purchased a new stake in Amgen in the 2nd quarter worth about $31,000. Finally, Bbjs Financial Advisors LLC acquired a new stake in Amgen during the 2nd quarter worth about $33,000. 76.50% of the stock is owned by hedge funds and other institutional investors.

Amgen Stock Performance

AMGN opened at $295.93 on Friday. Amgen Inc. has a 12-month low of $260.52 and a 12-month high of $346.85. The firm has a market capitalization of $159.07 billion, a P/E ratio of 37.89, a price-to-earnings-growth ratio of 2.69 and a beta of 0.60. The stock’s 50 day moving average price is $322.15 and its two-hundred day moving average price is $318.15. The company has a quick ratio of 0.96, a current ratio of 1.32 and a debt-to-equity ratio of 7.55.

Amgen (NASDAQ:AMGN) last released its earnings results on Wednesday, October 30th. The medical research company reported $5.58 EPS for the quarter, beating the consensus estimate of $5.11 by $0.47. The firm had revenue of $8.50 billion during the quarter, compared to analysts’ expectations of $8.50 billion. Amgen had a net margin of 13.00% and a return on equity of 168.35%. The business’s quarterly revenue was up 23.2% compared to the same quarter last year. During the same period in the prior year, the company earned $4.96 EPS. On average, equities analysts forecast that Amgen Inc. will post 19.51 earnings per share for the current year.

Amgen Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, December 9th. Investors of record on Monday, November 18th will be given a dividend of $2.25 per share. This represents a $9.00 dividend on an annualized basis and a yield of 3.04%. The ex-dividend date is Monday, November 18th. Amgen’s dividend payout ratio (DPR) is presently 115.24%.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on AMGN shares. Dbs Bank upgraded Amgen to a “strong-buy” rating in a report on Monday, September 16th. Sanford C. Bernstein initiated coverage on shares of Amgen in a research report on Thursday, October 17th. They issued an “outperform” rating and a $380.00 target price for the company. Jefferies Financial Group restated a “buy” rating and set a $380.00 price target on shares of Amgen in a report on Tuesday. Bank of America increased their price objective on Amgen from $325.00 to $330.00 and gave the stock a “neutral” rating in a report on Wednesday, August 7th. Finally, Deutsche Bank Aktiengesellschaft restated a “hold” rating and issued a $305.00 target price (down previously from $310.00) on shares of Amgen in a research note on Wednesday, August 7th. One investment analyst has rated the stock with a sell rating, thirteen have issued a hold rating, eleven have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $333.57.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.